HI
KPTI icon

Harbour Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Harbour Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.59K Buy
285
+200
+235% +$1.52K ﹤0.01% 3978
2025
Q4 		$626 Hold
85
– – ﹤0.01% 3516
2025
Q3 		$556 Hold
85
– – ﹤0.01% 3496
2025
Q2 		$366 Hold
85
– – ﹤0.01% 3418
2025
Q1 		$318 Sell
85
-2
-2% -$17 ﹤0.01% 3389
2024
Q4 		$879 Hold
87
– – ﹤0.01% 3195
2024
Q3 		$1.08K Hold
87
– – ﹤0.01% 3081
2024
Q2 		$1.13K Hold
87
– – ﹤0.01% 2972
2024
Q1 		$1.96K Hold
87
– – ﹤0.01% 2784
2023
Q4 		$1.13K Hold
87
– – ﹤0.01% 2799
2023
Q3 		$1.74K Hold
87
– – ﹤0.01% 2585
2023
Q2 		$2.33K Buy
87
+34
+64% +$1.46K ﹤0.01% 2505
2023
Q1 		$3.11K Hold
53
– – ﹤0.01% 2445
2022
Q4 		$2.72K Hold
53
– – ﹤0.01% 2439
2022
Q3 		$4K Hold
53
– – ﹤0.01% 2246
2022
Q2 		$4K Buy
+53
New +$4.86K ﹤0.01% 2246
2021
Q4 		$5K Sell
53
-134
-72% -$13.4K ﹤0.01% 2175
2021
Q3 		$16K Buy
187
+20
+12% +$2.08K ﹤0.01% 2417
2021
Q2 		$26K Sell
167
-173
-51% -$25.1K ﹤0.01% 2193
2021
Q1 		$54K Buy
+340
New +$71.6K ﹤0.01% 1657

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Harbour Investments's KPTI Position: Q1 2026 in Review

Harbour Investments increased its Karyopharm Therapeutics (KPTI) stake by 235% in Q1 2026, buying an estimated $1.52K and bringing the position to 285 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #3978.

Harbour Investments first reported a position in KPTI in Q1 2021 and has held it in 20 quarters since. The position peaked at $54K in Q1 2021. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Harbour Investments held 285 shares of Karyopharm Therapeutics worth $1.59K as of Q1 2026.
  • Harbour Investments bought 200 Karyopharm Therapeutics shares in Q1 2026, an estimated $1.52K.
  • Karyopharm Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #3978 holding.
  • Harbour Investments first reported a position in Karyopharm Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Harbour Investments's Karyopharm Therapeutics position peaked at $54K in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.